Fiera Capital Corp Increases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fiera Capital Corp increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 104,836 shares of the medical research company's stock after buying an additional 10,690 shares during the period. Fiera Capital Corp's holdings in Thermo Fisher Scientific were worth $55,646,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Northwest Financial Advisors purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth $29,000. Raleigh Capital Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company's stock valued at $41,000 after purchasing an additional 27 shares during the last quarter. Cedar Mountain Advisors LLC increased its position in shares of Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company's stock valued at $47,000 after purchasing an additional 46 shares during the last quarter. Pacific Capital Wealth Advisors Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $51,000. Finally, Financial Connections Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $53,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 0.3 %

Shares of Thermo Fisher Scientific stock traded down $1.87 on Thursday, reaching $597.15. The stock had a trading volume of 1,275,761 shares, compared to its average volume of 1,529,735. The stock has a market capitalization of $227.94 billion, a P/E ratio of 38.30, a P/E/G ratio of 2.45 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The company has a 50 day moving average price of $576.79 and a 200 day moving average price of $540.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts' consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific's dividend payout ratio is presently 10.01%.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,000 shares of company stock valued at $18,486,980. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating on the stock in a research report on Thursday, April 25th. The Goldman Sachs Group upped their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a research report on Wednesday, April 10th. Raymond James upped their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a report on Thursday, February 1st. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a "neutral" rating and a $620.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $607.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.